Effects of enteral immunonutrition enriched with multiple immunonutrients on clinical outcomes of patients who underwent gastric cancer surgery: a systematic review and meta-analysis - Takeaways - MDSpire

Effects of enteral immunonutrition enriched with multiple immunonutrients on clinical outcomes of patients who underwent gastric cancer surgery: a systematic review and meta-analysis

  • By

  • Mao Chen

  • Yan Duan

  • Yan He

  • Shan Zhong

  • Qin Li

  • Yin Zhao

  • June 17, 2026

  • 0 min

Share

  • 1

    Enteral immunonutrition (EIN) significantly reduces infectious complications and total complications compared to standard enteral nutrition (EN) in gastric cancer surgery patients.

  • 2

    EIN shortens the length of hospital stay by an average of 1.24 days and improves gastrointestinal tolerance in patients post-gastric cancer surgery.

  • 3

    EIN enhances immune parameters, increasing levels of IgG, IgM, IgA, and transferrin while reducing inflammatory markers like WBC and CRP.

  • 4

    Perioperative administration of EIN for 7–10 days yields the most significant clinical benefits, particularly in patients with nutritional risk.

  • 5

    The evidence for EIN's effectiveness is of moderate certainty for primary outcomes but low certainty for several secondary outcomes, necessitating further research.

Original Source(s)

Effects of enteral immunonutrition enriched with multiple immunonutrients on clinical outcomes of patients who underwent gastric cancer surgery: a systematic review and meta-analysis

  • by Mao Chen, Yan Duan, Yan He, Shan Zhong, Qin Li, Yin Zhao

  • June 17, 2026

Related Content

Trastuzumab emtansine versus trastuzumab plus pertuzumab for HER2-positive breast cancer with residual disease after neoadjuvant therapy: a real-world study

Case Report: Persistent severe thrombocytopenia after adjuvant ado-trastuzumab emtansine with sequential bone marrow findings and romiplostim support

Real-world effectiveness and safety of carfilzomib, pomalidomide, and dexamethasone in relapsed/refractory multiple myeloma: a retrospective analysis from China